Immunohistochemical demonstration of isocitrate dehydrogenase 1 (IDH1) mutation in a small subset of prostatic carcinomas

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 4, 2014, Pages 284-287

  Mauzo, Shakuntala H ^a   Lee, Michael ^a   Petros, John ^b   Hunter, Stephen ^a   Chang, Chi Ming ^c   Shu, Hui Kuo ^c   Bellail, Anita C ^a   Hao, Chunhai ^a   Cohen, Cynthia ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b Department of Urology ^*  (India)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancers; IDH1; mutation; prostate; thyroid

Indexed keywords

DNA; ISOCITRATE DEHYDROGENASE 1; MONOCLONAL ANTIBODY; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE;

ARTICLE; ASTROCYTOMA; BREAST CARCINOMA; COLORECTAL CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; GENE SEQUENCE; GLEASON SCORE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUTATIONAL ANALYSIS; OVARY CARCINOMA; PILOCYTIC ASTROCYTOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; SOLID TUMOR; SOMATIC MUTATION; THYROID ADENOMA; THYROID CARCINOMA; TISSUE MICROARRAY; WESTERN BLOTTING; BRAIN NEOPLASMS; CARCINOMA; GENETICS; PATHOLOGY; POINT MUTATION; PROSTATIC NEOPLASMS;

ASTROCYTOMA; BRAIN NEOPLASMS; CARCINOMA; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; MALE; POINT MUTATION; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 84898543617     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3182649d1c     Document Type: Article

References (19)

1. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321: 1807-1812.
2. Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116:597-602.
3. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-773.
4. Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174:1149-1153.
5. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469-474.
6. Bleeker FE, Lamba S, Leenstra S, et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat. 2009;30:7-11.
7. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110.
8. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361:1058-1066.
9. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28:2348-2355.
10. Kang MR, Kim MS, Oh JE, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer. 2009;125:353-355.
11. Murugan AK, Bojdani E, Xing M. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun. 2010;393:555-559.
12. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009;324:261-265.
13. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739-744.
14. Ward PS, Patel J, Wise DR, et al. The common feature of leukemiaassociated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225-234.
15. Bleeker FE, Atai NA, Lamba S, et al. The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 2010;119:487-494.
16. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27:4150-4154.
17. Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in lowgrade astrocytomas predict survival but not response to temozolomide. Neurology. 2009;73:1792-1795.
18. Kato Y, Jin G, Kuan CT, et al. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common gliomaderived mutation. Biochem Biophys Res Commun. 2009;390:547-551.
19. Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010;20:245-254.